相关实验视频

Updated: Jun 21, 2025

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

YTHDC1通过CDK6的m6A修饰加剧高葡萄糖诱导的视网膜血管内皮细胞损伤

Qi Zhou¹, Min Tian¹, Yang Cao¹

¹Department of Ophthalmology, Affiliated Hospital of Southwest Medical University, Luzhou City, Sichuan Province, 646000, China.

|July 8, 2024

概括

在糖尿病视网膜病变中,N6-甲基氨酸 (m6A) RNA修饰,特别是YTHDC1被上调,损害视网膜血管内皮细胞 (RVECs). 准YTHDC1-CDK6通路可能为糖尿病血管并发症提供新的治疗方法.

科学领域:

生物化学生物化学
分子生物学分子生物学
眼科医生眼科眼科

背景情况:

糖尿病视网膜病变 (DR) 是导致视力丧失的主要原因,其特征是视网膜血管内皮细胞 (RVECs) 功能障碍.
N6-甲基氨酸 (m6A) RNA修饰是真核生物中普遍存在的表观遗传机制,但其在DR中的作用仍然基本不明.

研究的目的:

研究m6ARNA修饰及其读者蛋白YTHDC1在糖尿病引起的RVEC功能障碍中的作用.
阐明涉及YTHDC1-CDK6轴在DR病变发生过程中的潜在分子机制.

主要方法:

定量实时PCR和西布洛特测定m6A水平和YTHDC1表达.
在体外测试 (CCK-8,Transwell,伤口愈合,管形成) 来评估RVECs的功能.
使用视网膜素消化和H&E染色进行体内研究,以评估组织病理变化.

主要成果:

在高葡萄糖诱导的RVEC中,m6ARNA甲基化和YTHDC1表达显著增加.
通过通过mRNA衰变抑制CDK6表达,YTHDC1过度表达损害了RVECs的活力,增殖,迁移和管形成.
YTHDC1的淘汰抑制了CDK6的核出口,并促进了其在核中的mRNA降解,而CDK6的过度表达在DR的小鼠模型中逆转了保护作用.

结论:

通过YTHDC1介导的m6A甲基化在调节糖尿病引起的RVEC功能障碍方面发挥着至关重要的作用.
YTHDC1-CDK6信号轴代表了治疗糖尿病视网膜病变的潜在治疗目标.

关键词:

在 CDK6 中,CDK6 是 CDK6 的代码.视网膜血管内皮细胞在 YTHDC1 中.m6A 一个很好的.

更多相关视频

Retinal Cryo-sections, Whole-Mounts, and Hypotonic Isolated Vasculature Preparations for Immunohistochemical Visualization of Microvascular Pericytes

Retinal Cryo-sections, Whole-Mounts, and Hypotonic Isolated Vasculature Preparations for Immunohistochemical Visualization of Microvascular Pericytes

Published on: October 7, 2018

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...